CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2017—SeraCare Life Sciences launched the industry’s first multiplexed inherited cancer reference material for inherited disease testing by next-generation sequencing, according to the company. The Seraseq Inherited Cancer DNA Mix reference materials were developed to validate the ability of synthetic reference materials to address technically challenging variants.
The mix addresses the lack of multiplexed reference materials for targeted NGS assays and is focused on seven genes associated with inherited cancer syndromes, including BRCA1 and BRCA2. This product combines over 20 pathogenic variants of diverse types in a well-characterized genomic background that can be used for assay development and analytical validation.
SeraCare Life Sciences, 508-244-6400